Adma Biologics (ADMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Company Performance - Adma Biologics (ADMA) closed at $17.70, down 1.28% from the previous trading session, underperforming the S&P 500's daily loss of 0.19% [1] - Over the past month, ADMA shares have decreased by 9.12%, lagging behind the Medical sector's gain of 0.48% and the S&P 500's gain of 2.26% [1] Upcoming Earnings - Investors are anticipating Adma Biologics' upcoming earnings disclosure, with Zacks Consensus Estimates predicting earnings of $0.57 per share and revenue of $0 million, reflecting year-over-year changes of +16.33% for earnings and 0% for revenue [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics should be monitored, as positive estimate revisions indicate optimism about the business outlook [3] Valuation Metrics - Adma Biologics is currently trading at a Forward P/E ratio of 21.87, which is a premium compared to its industry's Forward P/E of 20.92 [6] - The Medical - Biomedical and Genetics industry, to which Adma belongs, has a Zacks Industry Rank of 99, placing it in the top 41% of over 250 industries [6] Zacks Rank - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently rates Adma Biologics at 3 (Hold), with the consensus EPS estimate remaining steady over the past month [5]